Physician profile
Jori Danae Matushek
NPI 1467077578
$121,403.03
in general payments reported to CMS, 2019-2025
16 companies · $82K in 2025
The $82K reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $802 · 2022: $2,626 · 2023: $19K · 2024: $17K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Food and Beverage: $3,808 · Travel and Lodging: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,870.68 |
| Food and Beverage | $3,807.95 |
| Travel and Lodging | $1,296.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $112,088.23 | 2022-2025 | Omnipod, Omnipod |
| Tandem Diabetes Care, INC. | $2,604.57 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar Pharmaceuticals, INC. | $1,651.39 | 2021-2022 | |
| Medtronic, INC. | $1,464.78 | 2021-2025 | Minimed 780g |
| Mannkind Corporation | $916.23 | 2021-2025 | Afrezza |
| Ascendis Pharma Endocrinology INC | $750.38 | 2022-2025 | Skytrofa |
| Abbott Laboratories | $726.16 | 2021-2023 | Freestyle Libre 3 |
| Beta Bionics, INC. | $192.14 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $173.24 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $148.60 | 2023 | Gvoke Hypopen |
| Endo USA, INC. | $133.99 | 2025 | Supprelin |
| Neurocrine Biosciences, INC. | $132.33 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Dexcom, INC. | $115.26 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $107.44 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $73.29 | 2024-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jori Matushek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.